BullMarket.com Updates Outlook on Swine Flu Stocks
24 Julio 2009 - 8:46AM
PR Newswire (US)
PRINCETON, N.J., July 24 /PRNewswire/ -- BullMarket.com
(http://www.bullmarket.com/), an online investment newsletter
focused on long-term growth and income-generating stocks, has
provided subscribers with coverage of swine-flu stocks, including
Baxter International (NYSE:BAX), Novartis (NASDAQ:NVS), AstraZeneca
(NYSE:AZN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax
(NASDAQ:NVAX), and Hemispherx BioPharma (NYSE: HEB),among others.
All paid and trial subscribers to BullMarket.com can now receive
immediate access to the newsletter's exclusive daily reports. As a
subscriber, you'll also gain access to our Recommended List of
stocks, which outperformed the S&P 500 by 15% in 2008 and was
up over 16% year to date at the end of June. Start your 14-day free
trial today: https://www.bullmarket.com/subscribe/pr/?refer=BMR601P
In its daily report, BullMarket.com wrote: "The swine flu pandemic
-- yes, health officials believe we remain in the midst of one --
has faded from the view of many people, but there have been some
disturbing reports of late that could have an impact on both your
health and your portfolio." BullMarket.com looked at the following
topics, among others: -- What recent data suggests swine flu stocks
could go on another speculation-filled run this fall? -- Which of
the small-cap swine flu stocks looks most interesting? -- Do any of
the large-cap swine flu stocks look like good investments? About
BullMarket.com: Launched in 1997, BullMarket.com has a strong track
record of creating wealth for its subscribers by providing sound,
long-term investing advice. The BullMarket.com Recommended List
includes about 50 companies across all major industries, including
Financials, Healthcare, Energy, Technology, and Retail, among
others. BullMarket.com is one of the oldest continuously published
investment newsletters online, and its Recommended List has
consistently outperformed the major market indices. NOTE: This
release was published by Indie Research Advisors, LLC, a registered
investment advisor with CRD #131926. Interested parties may visit
adviserinfo.sec.gov for additional information. Past performance
does not guarantee future results. Investors should always research
companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or
sell any security. Contact: Marcie Martin, Bull Market Report,
+1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC CONTACT:
Marcie Martin, Bull Market Report, +1-888-278-5515 Web Site:
http://www.bullmarket.com/
Copyright